Secnidazole hemihydrate  (Synonyms: 塞克硝唑半水合物; RP-14539 hemihydrate; PM-185184 hemihydrate)

Secnidazole (RP-14539) hemihydrate is an orally active azole antibiotic and a imidazole mitigator of Serratia marcescens virulence. Secnidazole hemihydrate, as an analog of acylhomoserine lactones, effectively inhibits QS resulting in the attenuation of Pseudomonas aeruginosa pathogenesis. Secnidazole hemihydrate has antimicrobial activity against many anaerobic Gram-negative and Gram-positive bacterial species in vitro. Secnidazole hemihydrate can be used for the research of various diseases, such as amoebiasis and giardiasis, and bacterial vaginitis^[1][2][3].

Secnidazole (RP-14539) hemihydrate (0-5000 μM; 5 or 10 min) inhibits CYP2C19 and CYP3A4, with IC₅₀ values of 3873 μM and 3722 μM, respectively^[2].
Secnidazole hemihydrate (0-5000 μM; 5 or 10 min) does not exhibit time-dependent inhibition^[2].
Secnidazole hemihydrate (0-5000 μM; 5 or 10 min) has an apparent IC₅₀ value of 503 μM for direct inhibition of human ALDH2^[2].
Secnidazole hemihydrate (0-5000 μM; 5 or 10 min) has concentration-dependent inhibition at higher concentration with some of the CYP isoforms notably CYP2A6, CYP2B6, and CYP2D6^[2].
Secnidazole hemihydrate (10 μL; 20 h; the secnidazole solution was two-fold serially diluted using Mueller–Hinton broth to obtain dilutions ranging from 80 to 0.3125 mg/mL) inhibits S.marcescens growth with a MIC₅₀ value of 10 mg/mL^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Secnidazole (RP-14539) hemihydrate (100 μL; ip.; for 5 days) has protective activity against S.marcescens pathogenesis and can diminish its pathogenesis in mice^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

194.19

C₇H₁₃N₃O₄

227622-73-3

塞克硝唑半水合物

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Secnidazole. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases, 25 February 2020.  [Content Brief]

  [2]. Helen S Pentikis, et al. In vitro metabolic profile and drug-drug interaction assessment of secnidazole, a high-dose 5-nitroimidazole antibiotic for the treatment of bacterial vaginosis. Pharmacol Res Perspect. 2020 Aug;8(4):e00634.  [Content Brief]

  [3]. Ahdab N Khayyat, et al. Secnidazole Is a Promising Imidazole Mitigator of Serratia marcescens Virulence. Microorganisms. 2021 Nov 11;9(11):2333.  [Content Brief]